BPC-157 vs TB-500
Dosing, half-life, mechanism, benefits, and safety — side by side.
BPC-157
ResearchBody Protection Compound for accelerated tissue healing and repair
Half-Life
<30 minutes
Route
SC/Oral
Dose
200-500 mcg Daily
MW
1419.53 Da
TB-500
ResearchSynthetic thymosin beta-4 for tissue repair and inflammation reduction
Half-Life
Variable
Route
SC
Dose
2-8 mg 2-3x/week
MW
4963.00 Da
Quick Reference
| BPC-157 | TB-500 | |
|---|---|---|
| Category | N/A | N/A |
| Route | SC/Oral | SC |
| Typical Dose | 200-500 mcg Daily | 2-8 mg 2-3x/week |
| Frequency | Daily | N/A |
| FDA Approved | No | No |
| WADA Status | Banned | Banned |
⏱ Pharmacokinetics
| BPC-157 | TB-500 | |
|---|---|---|
| Half-Life | <30 minutes | Variable |
| Research Status | Investigational - Not approved for human use | Investigational - Not approved for human use |
| CAS Number | 137525-51-0 | 77591-33-4 |
Molecular
| BPC-157 | TB-500 | |
|---|---|---|
| Molecular Weight | 1419.53 | 4963.00 |
| Molecular Formula | C62H98N16O22 | C38H68N10O14 |
| Sequence Length | 15 aa | 7 aa |
| Mechanism | Promotes angiogenesis and tissue healing | Thymosin Beta-4 fragment that enhances cell migration |
Key Benefits
| BPC-157 | TB-500 | |
|---|---|---|
| Benefits | Accelerated wound healing; Tendon and ligament repair; Muscle tissue regeneration; Anti-inflammatory effects; Gastrointestinal protection; Accelerated healing; Tissue repair; Anti-inflammatory | Accelerated recovery; Enhanced recovery; Injury healing; Muscle repair; Angiogenesis; Enhanced wound healing; Improved flexibility; Tissue regeneration |
Safety & Warnings
| BPC-157 | TB-500 | |
|---|---|---|
| Safety Note | No human clinical trials completed. Research compound only - not for human consumption. | Limited human safety data. Research compound only - not approved for therapeutic use. |
| Side Effects | 110 μg for a 150lb person; 145 μg for a 200lb person; 180 μg for a 250lb person; No toxicity reported; No adverse reactions documented; No human trial toxicity; Nausea; Dizziness | Fatigue; Dizziness; Well tolerated in trials; Limited human safety data; Potential tumor promotion; WADA prohibited substance; Mild-Moderate side effect; Side effect reported |
| Athlete Warning | 🛑 WADA BANNED - Prohibited in competitive sports as healing peptide | 🛑 WADA BANNED - Prohibited in competitive sports as healing and regeneration peptide |
Which should you choose?
Both BPC-157 and TB-500 have meaningful research support. The right choice depends on your specific goals, tolerance, and whether an FDA-approved option fits your needs.
BPC-157 vs TB-500 — FAQ
Which has a longer half-life: BPC-157 or TB-500?
BPC-157 has a half-life of ~<30 minutes while TB-500 has a half-life of ~Variable. A longer half-life generally means less frequent dosing and more stable levels.
Can I stack BPC-157 and TB-500 together?
Whether BPC-157 and TB-500 can be stacked depends on their mechanisms and receptor targets. Use the stack compatibility checker to analyze synergies and conflicts before combining any peptides.
Which is better: BPC-157 or TB-500?
There is no universal "better" peptide — it depends on your goal. BPC-157 is Promotes angiogenesis and tissue healing. TB-500 is Thymosin Beta-4 fragment that enhances cell migration. Choose based on your primary goal and research profile.
More Comparisons
Tirzepatide vs Semaglutide
Compare side-by-side →
Retatrutide vs Tirzepatide
Compare side-by-side →
Semaglutide vs Retatrutide
Compare side-by-side →
Ipamorelin vs Sermorelin
Compare side-by-side →
CJC-1295 vs Sermorelin
Compare side-by-side →
MK-677 vs Ipamorelin
Compare side-by-side →
GHK-Cu vs AHK-Cu
Compare side-by-side →
Selank vs Semax
Compare side-by-side →
MOTS-c vs NAD+
Compare side-by-side →
PT-141 vs Melanotan-II
Compare side-by-side →
Tesamorelin vs CJC-1295
Compare side-by-side →
HGH vs MK-677
Compare side-by-side →
Semaglutide vs Liraglutide
Compare side-by-side →